Healthcare / BiotechnologyTokyo
$332.00
-7.00 (-2.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-857.0M · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-4.4%
↓Gross Margin
88.0%
↑Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+112.5%
FCF CAGR
—
FCF margin
13.3%
FCF / Net income
-0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $961.1M · net income $-140.8M · FCF $128.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $961.1M | $961.1M | $269.5M | $229.1M | $100.1M |
| Net Income | $-140.8M | $-140.8M | $-763.7M | $-778.8M | $-767.7M |
| EBITDA | $-99.1M | $-99.1M | $-723.9M | $-738.3M | $-726.9M |
| EPS | -4.22 | -4.22 | -24.66 | -26.97 | -27.34 |
| Gross Margin | 88.0% | 88.0% | 80.6% | 90.3% | 84.8% |
| Operating Margin | -9.4% | -9.4% | -282.1% | -352.2% | -741.2% |
| Net Margin | -14.7% | -14.7% | -283.4% | -340.0% | -767.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.39 | 0.40 | 0.41 |
| Current Ratio | 16.81 | 16.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $128.0M | $128.0M | $-887.8M | $-857.0M | $-1.13B |
| Returns | |||||
| ROE | -4.4% | -4.4% | -32.1% | -28.3% | -24.9% |
| Valuation | |||||
| P/B | 3.46 | 3.46 | 3.58 | 3.90 | 5.36 |
| Growth & Yield | |||||
| Revenue Growth | 256.6% | 256.6% | 17.6% | 128.8% | — |
| EPS Growth | 82.9% | 82.9% | 8.6% | 1.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-24.66 → -4.22
Residual
-2.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.